1. A 74-year-old man with a 9-year history of Parkinson's disease on carbidopa/levodopa 25/100 mg five times daily and rasagiline 1 mg daily develops distressing visual hallucinations and persecutory delusions over 6 weeks. His neurologist has already optimized the dopaminergic regimen by removing rasagiline and reducing levodopa to the minimum dose tolerated for motor function, but the psychosis persists. An antipsychotic is now required. The neurology consultant is asked which antipsychotic is appropriate. Which of the following best describes the pharmacological constraints governing antipsychotic selection in PD psychosis and identifies the agents that satisfy those constraints?

• A) All second-generation antipsychotics are safe in PD psychosis because they preferentially block 5-HT2A receptors rather than D2 receptors; the high 5-HT2A-to-D2 blockade ratio of agents such as risperidone and olanzapine means they do not worsen parkinsonism and can be prescribed freely in PD without motor monitoring; haloperidol and other first-generation antipsychotics are contraindicated because their pure D2 blockade worsens motor function.
• B) No antipsychotic can be safely used in patients with PD on levodopa because all antipsychotics — regardless of receptor profile — require partial D2 blockade for antipsychotic efficacy, and any degree of D2 blockade in a patient whose motor function depends entirely on D2 receptor stimulation will produce clinically unacceptable worsening of parkinsonism; the correct management is electroconvulsive therapy (ECT) as the only effective treatment for PD psychosis that does not risk motor deterioration.
• C) The critical pharmacological constraint in PD psychosis is that the antipsychotic must not block striatal D2 receptors to a degree that worsens motor function; first-generation antipsychotics (haloperidol, fluphenazine) and most second-generation antipsychotics with significant D2 affinity (risperidone, olanzapine, aripiprazole) are contraindicated or carry substantial motor risk; the agents appropriate for PD psychosis are quetiapine (low D2 affinity, rapid receptor dissociation), clozapine (very low D2 affinity with REMS enrollment required for agranulocytosis monitoring with weekly CBC for 6 months then biweekly), and pimavanserin (a selective 5-HT2A/2C inverse agonist with no D2 activity, FDA-approved specifically for PD psychosis), which reduce psychosis without blocking the D2 receptors mediating levodopa's motor benefit.
• D) The appropriate antipsychotic in PD psychosis is aripiprazole, a D2 partial agonist that stabilizes dopaminergic tone by acting as an agonist when dopamine levels are low (during off periods) and as an antagonist when dopamine levels are high (during on periods with psychosis); this pharmacodynamic profile uniquely adapts to the fluctuating dopamine concentrations of PD and provides antipsychotic benefit during on periods without worsening motor function during off periods.
• E) The antipsychotic of choice in PD psychosis is intramuscular haloperidol at low doses (0.5 mg daily), which produces selective D2 blockade in mesolimbic circuits without affecting nigrostriatal D2 receptors because the parenteral route bypasses first-pass hepatic metabolism and achieves mesolimbic-selective drug distribution; oral haloperidol is contraindicated but the intramuscular route is safe in PD because the pharmacokinetic profile of IM administration targets limbic rather than striatal dopamine receptors.

2. A 69-year-old woman with advanced Parkinson's disease has been on levodopa-carbidopa intestinal gel (LCIG) infusion for 8 months with excellent motor control — virtually no off time and only mild dyskinesia. She calls the clinic on a Tuesday morning reporting that since waking she has been in a severe off state, with marked rigidity and inability to walk, that has not responded to her usual oral levodopa rescue tablets. She had normal pump function and motor control the previous evening. Her caregiver reports the pump is running normally with no alarms, the cassette is full, and the external tubing appears intact. Which of the following best identifies the most likely cause of this acute motor deterioration and the appropriate initial management step?

• A) The most likely cause is internal tube displacement — specifically migration of the jejunal extension tube back into the stomach, which can occur without external signs of malfunction since the pump continues to run, the cassette empties, and external tubing remains intact; gel delivered into the stomach is subject to the same erratic gastric emptying and variable absorption that LCIG was designed to bypass, producing a sudden loss of the continuous levodopa delivery that had maintained motor control; the initial management is urgent radiological confirmation of tube position (abdominal X-ray showing the jejunal tube tip position) and endoscopic repositioning or replacement; oral carbidopa/levodopa should be administered immediately to bridge motor function while awaiting the procedure, and subcutaneous apomorphine can be used if oral rescue is inadequate.
• B) The most likely cause is LCIG pump battery failure producing intermittent delivery interruptions that occur too briefly to trigger alarms but are sufficient to reduce effective levodopa delivery; the management is replacing the pump battery pack and restarting the infusion at 110% of the usual maintenance rate for 2 hours to compensate for the delivery gap.
• C) The most likely cause is tolerance to the continuous dopaminergic stimulation from LCIG, which after 8 months produces progressive D2 receptor internalization and downregulation that requires a 24-hour drug holiday to restore receptor sensitivity; management is stopping the infusion for 24 hours under hospital supervision, then restarting at a 20% higher maintenance rate.
• D) The most likely cause is spontaneous peritonitis at the PEG-J site causing systemic inflammatory response that reduces CNS dopamine receptor sensitivity through cytokine-mediated signal transduction; management is empirical broad-spectrum antibiotics and temporary discontinuation of LCIG until the inflammatory response resolves, after which sensitivity is restored and infusion can resume at the prior rate.
• E) The most likely cause is that the levodopa concentration in the cassette has degraded overnight due to oxidative instability of the gel formulation at room temperature; the levodopa in the cassette has been converted to dopamine by atmospheric oxygen, producing a cassette that delivers dopamine rather than levodopa, which cannot cross the blood-brain barrier; management is replacing the cassette with a freshly refrigerated unit and restarting the infusion.

3. A 68-year-old man with Parkinson's disease and treatment-resistant depression is seen by his psychiatrist, who proposes adding phenelzine — a non-selective, irreversible MAO inhibitor — to his existing regimen of carbidopa/levodopa 25/100 mg four times daily. The patient's neurologist urgently contacts the psychiatrist to explain that this combination is contraindicated. Which of the following best explains the specific mechanism of the dangerous interaction between non-selective MAO inhibitors and levodopa, and identifies the pharmacological basis for why selective MAO-B inhibitors used in PD (selegiline, rasagiline) do not carry the same contraindication?

• A) Non-selective MAO inhibitors such as phenelzine inhibit both MAO-A and MAO-B in peripheral sympathetic nerve terminals, preventing norepinephrine reuptake and producing a hyperadrenergic state; levodopa amplifies this interaction by providing substrate for dopamine synthesis in these terminals, which is then converted to norepinephrine by dopamine beta-hydroxylase and cannot be degraded; MAO-B-selective inhibitors avoid this because MAO-B is not expressed in sympathetic nerve terminals.
• B) Phenelzine directly inhibits peripheral AADC, competing with carbidopa for the AADC active site; the combination of phenelzine-mediated and carbidopa-mediated AADC inhibition eliminates all peripheral levodopa conversion, causing accumulation of unmetabolized levodopa to toxic plasma levels that produce vasoconstriction via direct levodopa binding to alpha-1 adrenergic receptors; selective MAO-B inhibitors do not inhibit AADC and therefore do not produce this accumulation.
• C) Phenelzine inhibits MAO-A in the gut wall, eliminating the first-pass intestinal MAO-A metabolism of tyramine from dietary sources; the resulting systemic tyramine surge triggers massive norepinephrine release from sympathetic terminals producing hypertensive crisis; levodopa is incidental to this interaction and the contraindication applies equally to any patient on phenelzine regardless of whether they take levodopa.
• D) Non-selective MAO inhibitors such as phenelzine block MAO-B in the striatum, preventing the catabolism of levodopa-derived dopamine to DOPAC; the resulting striatal dopamine accumulation reaches concentrations that activate D1 receptors in the hypothalamic thermoregulatory center, producing hyperthermia indistinguishable from NMS; selective MAO-B inhibitors at standard doses produce the same striatal dopamine accumulation but at a lower rate that the hypothalamus can compensate for.
• E) Non-selective MAO inhibitors such as phenelzine inhibit both MAO-A and MAO-B throughout the body, including in peripheral sympathetic nerve terminals and in the gut wall; when levodopa is administered, it is converted to dopamine in peripheral tissues (despite carbidopa, some peripheral conversion occurs), and this dopamine — normally catabolized by MAO — accumulates in sympathetic nerve terminals and is released in large amounts, triggering a potentially fatal hypertensive crisis from massive norepinephrine co-release and direct vascular dopamine receptor stimulation; selective MAO-B inhibitors at standard PD doses (selegiline 5 to 10 mg, rasagiline 1 mg) preserve MAO-A activity, which continues to catabolize peripheral dopamine and prevent its dangerous accumulation in sympathetic terminals, explaining why the levodopa interaction does not occur at selective doses.

4. A 71-year-old woman with Parkinson's disease and refractory wearing-off was started on tolcapone 100 mg three times daily 10 weeks ago after entacapone failed to provide adequate benefit. Her motor control has improved substantially. At her scheduled 10-week liver function check, her ALT is 68 U/L (upper limit of normal 40 U/L — 1.7× ULN) and AST is 52 U/L (1.3× ULN). She is asymptomatic with no jaundice, nausea, abdominal pain, or fatigue. Her neurologist must decide whether to continue tolcapone. Which of the following best describes the correct management decision and the pharmacological rationale for the monitoring threshold that governs it?

• A) An ALT of 1.7× ULN is within an acceptable range for tolcapone therapy and no action is required; the tolcapone label specifies discontinuation only when ALT exceeds 10× ULN, reflecting the threshold at which hepatocyte regenerative capacity is exceeded and fulminant failure becomes likely; transaminase elevations below this threshold represent an adaptive hepatic response to COMT inhibition that does not progress to clinical hepatitis.
• B) Tolcapone must be discontinued when liver enzymes rise above the upper limit of normal on any scheduled or unscheduled check, per the FDA label requirement; an ALT of 1.7× ULN constitutes an above-normal result that mandates immediate tolcapone discontinuation regardless of the absence of symptoms; the rationale is that the three fatal post-marketing cases of fulminant hepatic failure occurred in patients in whom transaminase elevations were initially modest and asymptomatic before rapid progression to hepatic failure, establishing that any above-normal transaminase elevation in a tolcapone-treated patient represents a signal that cannot be safely observed.
• C) An ALT of 1.7× ULN in an asymptomatic patient on tolcapone should be managed by reducing the tolcapone dose from 100 mg three times daily to 50 mg three times daily and rechecking liver function in 2 weeks; if the ALT normalizes at the lower dose, full-dose therapy can be cautiously resumed with weekly monitoring; this dose-reduction strategy is endorsed by the FDA label as the preferred initial response to mild transaminase elevation.
• D) The transaminase elevation likely reflects a drug interaction between tolcapone and rasagiline rather than direct tolcapone hepatotoxicity; both drugs are metabolized by MAO-B and compete for the same hepatic enzyme system, causing accumulation of a shared hepatotoxic intermediate; the correct management is discontinuing rasagiline rather than tolcapone, rechecking liver function in 4 weeks, and continuing tolcapone if enzymes normalize after rasagiline removal.
• E) An ALT of 1.7× ULN in an asymptomatic patient on tolcapone warrants repeat testing in 2 weeks before any therapeutic decision; if the ALT remains below 3× ULN on the repeat test, tolcapone may be continued with monthly monitoring; if ALT rises above 3× ULN or symptoms develop, discontinuation should be considered; this staged response mirrors the approach used for statin-induced transaminase elevations where mild asymptomatic enzyme rises rarely predict clinical hepatotoxicity.

5. A 77-year-old woman with Parkinson's disease and mild-to-moderate dementia has clear wearing-off that worsens predictably after protein-containing meals. Her neurologist had previously recommended a protein redistribution diet — concentrating protein intake at the evening meal — to reduce LAT1 competition with levodopa during the day. Her daughter reports that this dietary strategy has proven impossible to implement because her mother becomes confused and agitated when her routine meals are altered and cannot understand or cooperate with the dietary instructions. The neurologist now seeks a pharmacological strategy that addresses the same mechanistic problem without requiring dietary modification. Which of the following best identifies the appropriate pharmacological alternative and explains why it addresses the LAT1 competition problem?

• A) Switching to levodopa methyl ester (a more soluble levodopa prodrug) provides faster gastric emptying and higher peak plasma levodopa concentrations that outcompete dietary amino acids at LAT1 by mass action, achieving adequate BBB transport even in the presence of elevated plasma amino acids from dietary protein; the dose required is 30% lower than standard carbidopa/levodopa because the methyl ester has higher oral bioavailability.
• B) Adding domperidone 10 mg three times daily before meals accelerates gastric emptying, delivering levodopa to the proximal jejunum before dietary amino acids from the concurrent meal are absorbed and reach peak luminal concentrations; by shifting the timing of levodopa arrival at LAT1 earlier relative to the amino acid bolus, domperidone restores the competitive advantage of levodopa at the transporter without requiring dietary protein restriction.
• C) Adding pyridoxine 50 mg daily increases peripheral AADC activity, converting more levodopa to dopamine before the LAT1 competition can occur at the BBB; because dopamine does not require LAT1 for its pharmacological effect on peripheral dopamine receptors, the increase in peripheral dopamine production compensates for the reduction in CNS levodopa delivery caused by LAT1 competition from dietary amino acids.
• D) Adding entacapone to each levodopa dose reduces peripheral COMT-mediated conversion of levodopa to 3-O-methyldopa (3-OMD), which serves two complementary purposes: it extends levodopa plasma half-life by reducing the competing metabolic pathway, and it reduces 3-OMD accumulation — 3-OMD is itself a large neutral amino acid that competes with levodopa at LAT1 at both intestinal and BBB sites, so reducing its steady-state concentration relieves a pharmacologically controllable component of the LAT1 competition burden without requiring any change in the patient's diet or meal timing.
• E) Increasing the carbidopa dose from 25 mg to 50 mg per tablet (by switching to the 50/200 mg CR formulation) reduces peripheral dopamine production more completely, which reduces the peripheral dopaminergic stimulation of area postrema receptors that normally triggers an inhibitory reflex reducing LAT1 transporter expression at the BBB after protein-rich meals; higher carbidopa doses maintain LAT1 surface expression at the BBB throughout the day regardless of meal composition.

6. A 67-year-old man with advanced Parkinson's disease and frequent unpredictable off episodes is being initiated on subcutaneous apomorphine rescue injections. His movement disorders neurologist explains that a specific antiemetic pretreatment protocol must be started before the first apomorphine dose and maintained for several weeks. Which of the following best explains the pharmacological rationale for antiemetic pretreatment before apomorphine initiation, identifies the correct antiemetic agent and its mechanism, and explains why standard antiemetic agents used in other contexts are inappropriate in this patient?

• A) Apomorphine is a potent direct dopamine receptor agonist that produces severe nausea at initiation because it stimulates D2 receptors in the area postrema, a chemoreceptor trigger zone outside the BBB that is directly exposed to systemic dopamine agonist concentrations; domperidone — a peripheral D2 antagonist that does not cross the BBB — is the antiemetic of choice because it blocks area postrema D2 receptors and prevents nausea without entering the CNS and without blocking the striatal D2 receptors that mediate apomorphine's therapeutic antiparkinsonian effect; metoclopramide is contraindicated because it is a central and peripheral D2 antagonist that crosses the BBB and would block striatal dopamine receptors, worsening parkinsonism; ondansetron is ineffective for dopamine agonist-induced nausea because it blocks 5-HT3 receptors rather than D2 receptors, and has been associated with prolongation of the QTc interval when combined with apomorphine.
• B) Apomorphine produces nausea through direct gastric irritation from its acidic pH in the subcutaneous injection solution; domperidone pretreatment prevents nausea by stimulating gastric motility and accelerating gastric emptying, reducing acid pooling at the injection site through a gastroprokinetic mechanism; metoclopramide is avoided because its gastroprokinetic effect is excessive and causes diarrhea; ondansetron is the preferred alternative when domperidone is unavailable because it reduces gastric acid secretion and neutralizes the injection site pH.
• C) Apomorphine nausea is mediated by histamine H1 receptor stimulation in the vestibular nucleus; pretreatment with domperidone is effective because it has H1 antihistamine properties at the doses used for apomorphine pretreatment in addition to its D2 antagonist activity; prochlorperazine is avoided because its H1 blockade is too potent and causes excessive sedation; ondansetron can be used as an alternative antiemetic when domperidone is unavailable because it has both H1 and 5-HT3 antagonist properties at therapeutic doses.
• D) Apomorphine nausea results from peripheral serotonin release from enterochromaffin cells in the proximal small intestine triggered by the subcutaneous dopamine concentration gradient; domperidone pretreatment works by preventing serotonin release through D2-mediated inhibition of enterochromaffin cell secretion; metoclopramide is preferred over domperidone in patients with cardiac disease because it does not prolong the QTc interval; ondansetron is contraindicated because it paradoxically stimulates enterochromaffin serotonin release in the presence of apomorphine.
• E) Apomorphine nausea is caused by peripheral conversion of apomorphine to norapomorphine by COMT in the gut wall, and norapomorphine is the actual emetogenic compound; domperidone inhibits peripheral COMT and prevents norapomorphine formation; metoclopramide cannot be used because it activates COMT expression; patients on entacapone for wearing-off actually require no antiemetic pretreatment before apomorphine because entacapone already inhibits the COMT-mediated norapomorphine formation that causes the nausea.

7. A 73-year-old man with Parkinson's disease and stage 4 chronic kidney disease (eGFR 22 mL/min/1.73m²) is being managed on carbidopa/levodopa 25/100 mg four times daily. His nephrologist asks whether the levodopa regimen requires adjustment for his renal impairment and whether any metabolites of levodopa accumulate to clinically relevant levels in severe CKD. Which of the following most accurately characterizes levodopa's pharmacokinetic behavior in severe renal impairment and the appropriate clinical approach?

• A) Levodopa itself undergoes significant renal tubular reabsorption via the same transporter that reabsorbs filtered amino acids; in severe CKD the loss of functional tubular mass reduces levodopa reabsorption, causing a paradoxical increase in urinary levodopa excretion and a shortening of levodopa's effective plasma half-life; the dose must be increased by approximately 40% to compensate for the reduced renal reabsorption and maintain therapeutic plasma concentrations.
• B) Levodopa is primarily eliminated by renal excretion as unchanged drug via OAT1 (organic anion transporter 1) in the proximal tubule; in severe CKD with eGFR below 30, the reduced OAT1 transport capacity causes levodopa accumulation with a prolonged plasma half-life and markedly elevated peak concentrations; the standard recommendation is to reduce each individual levodopa dose by 50% while maintaining the same dosing frequency to prevent peak-concentration toxicity from levodopa accumulation.
• C) Levodopa itself is metabolized primarily by AADC and COMT rather than by renal excretion, and its plasma half-life is not materially prolonged by renal impairment; however, levodopa's principal metabolites — including 3-O-methyldopa (3-OMD) and homovanillic acid (HVA) — are renally excreted, and in severe CKD these metabolites accumulate to higher steady-state plasma levels; the clinical significance is that elevated 3-OMD further increases LAT1 competition at the BBB, potentially worsening levodopa's therapeutic effect; dose adjustment of levodopa itself is not routinely required for renal impairment, but the clinician should be alert to increased wearing-off attributable to 3-OMD accumulation and consider adding entacapone to reduce 3-OMD generation.
• D) In severe CKD, reduced renal clearance of carbidopa (which is excreted unchanged by the kidney) causes carbidopa accumulation leading to excessive peripheral AADC inhibition; paradoxically, the excess carbidopa eventually begins crossing the blood-brain barrier at the elevated plasma concentrations achieved in CKD, inhibiting central AADC and reducing therapeutic dopamine synthesis in the striatum; the management is switching to levodopa monotherapy without carbidopa in patients with eGFR below 25.
• E) Levodopa's volume of distribution is primarily determined by renal plasma flow, and in severe CKD the reduced renal plasma flow causes redistribution of levodopa from peripheral tissues into the CNS, producing neurotoxic CNS levodopa concentrations at standard doses; clinical manifestations include hallucinations, severe dyskinesia, and seizures; the management is reducing the levodopa dose by 75% and monitoring for CNS toxicity signs with each dose change.

8. A 70-year-old woman with Parkinson's disease on selegiline 5 mg twice daily and carbidopa/levodopa undergoes a painful orthopedic procedure and is prescribed meperidine (pethidine) 50 mg every 4 hours as needed for postoperative pain by the surgical team. The pharmacist intervenes urgently. Twelve hours after her first meperidine dose she develops agitation, diaphoresis, fever of 38.9°C, hyperreflexia, clonus, and generalized myoclonus. Which of the following best identifies the syndrome, explains the specific pharmacological mechanism of the selegiline-meperidine interaction, and identifies the broader opioid class implication?

• A) This is neuroleptic malignant syndrome triggered by meperidine's D2 receptor antagonist properties interacting with selegiline's MAO-B inhibition; selegiline amplifies meperidine's D2 blockade by preventing dopamine catabolism, causing a paradoxical dopamine excess followed by receptor internalization that produces the NMS triad; all opioids with D2 antagonist activity (meperidine, tramadol, fentanyl) are contraindicated with MAO inhibitors for this reason.
• B) This is an acute cholinergic crisis from inhibition of acetylcholinesterase by meperidine's normeperidine metabolite; selegiline inhibits MAO-B-mediated normeperidine clearance, causing normeperidine accumulation that inhibits acetylcholinesterase and produces the cholinergic toxidrome; all opioids that generate normeperidine analogs are contraindicated with MAO inhibitors; pure opioids such as morphine and oxycodone are safe because they do not produce normeperidine-like metabolites.
• C) This is opioid-induced respiratory depression amplified by selegiline's inhibition of cytochrome P450-mediated meperidine clearance; selegiline is a potent CYP2D6 inhibitor at standard doses, reducing meperidine metabolism and elevating plasma concentrations to toxic levels; the clinical picture reflects meperidine toxicity rather than a drug interaction at a pharmacodynamic receptor; naloxone should be administered immediately and will fully reverse the syndrome.
• D) This is a hypertensive crisis from meperidine's inhibition of norepinephrine reuptake combined with selegiline's prevention of norepinephrine catabolism; the combination produces systemic norepinephrine accumulation that causes the cardiovascular and autonomic features; serotonergic opioids (meperidine, tramadol) are contraindicated but pure mu-agonists (morphine, oxycodone, hydromorphone) are safe because they do not inhibit norepinephrine reuptake.
• E) This is serotonin syndrome caused by meperidine's serotonin reuptake inhibitor (SRI) properties combined with selegiline's MAO inhibition; meperidine — unlike most opioids — inhibits the serotonin transporter (SERT), preventing serotonin reuptake; selegiline prevents serotonin catabolism by MAO (both MAO-A and MAO-B metabolize serotonin to some degree); the combination produces serotonin accumulation manifesting as the serotonin syndrome triad of mental status change, autonomic instability, and neuromuscular abnormalities (hyperreflexia, clonus, myoclonus); the contraindication extends to tramadol (which also inhibits SERT and norepinephrine reuptake) and to other MAO inhibitors at any dose; opioids without serotonergic activity — morphine, oxycodone, hydromorphone, buprenorphine — are generally considered safe with MAO-B inhibitors at standard PD doses.

9. A movement disorders fellow is counseling a 65-year-old man with Parkinson's disease about rescue options for his off episodes. The patient asks for a head-to-head comparison between inhaled levodopa (Inbrija) and subcutaneous apomorphine as rescue agents and wants to understand the pharmacokinetic and practical differences that would influence the choice between them. Which of the following most accurately compares these two agents across the dimensions of onset of effect, route of administration, need for antiemetic pretreatment, and the clinical factors that favor one over the other?

• A) Inhaled levodopa and subcutaneous apomorphine have identical onset times of approximately 5 minutes because both achieve systemic absorption within the same time frame — inhaled levodopa via pulmonary capillary absorption and apomorphine via subcutaneous capillary absorption; the choice between them is determined entirely by patient preference for pulmonary versus subcutaneous delivery, and both require domperidone pretreatment to prevent nausea at initiation.
• B) Inhaled levodopa produces motor improvement within approximately 10 to 30 minutes of inhalation via pulmonary capillary absorption into the systemic circulation, followed by BBB transit and CNS conversion to dopamine — a multi-step process that limits the speed of onset; subcutaneous apomorphine, as a direct dopamine receptor agonist, acts within approximately 5 to 15 minutes because it bypasses the conversion steps and directly activates striatal D1 and D2 receptors after subcutaneous absorption; apomorphine requires domperidone antiemetic pretreatment for several weeks at initiation while inhaled levodopa does not require scheduled antiemetic pretreatment; inhaled levodopa is favored in patients who cannot self-inject or who have underlying pulmonary disease that is not severe enough to contraindicate its use, while apomorphine is favored when faster onset is required, when pulmonary disease contraindicates the inhaled route, or when the patient can be trained for self-injection.
• C) Subcutaneous apomorphine has a slower onset than inhaled levodopa because subcutaneous tissue has lower vascularity than the alveolar capillary bed; apomorphine reaches peak effect at approximately 45 to 60 minutes after injection, while inhaled levodopa peaks within 5 to 10 minutes; both agents require antiemetic pretreatment — domperidone for inhaled levodopa and ondansetron for apomorphine — initiated 3 days before the first dose.
• D) Both inhaled levodopa and subcutaneous apomorphine require conversion to dopamine in dopaminergic nerve terminals before exerting motor benefit; apomorphine is converted to dopamine by a stereospecific reductase in nigrostriatal terminals while inhaled levodopa is converted by AADC; the difference in onset reflects the different kinetics of these two enzymes, with the apomorphine-reductase pathway being approximately 3 times faster than AADC-mediated conversion.
• E) Inhaled levodopa is the preferred rescue agent in all patients with Parkinson's disease because it produces dopamine directly in the striatum without systemic distribution — it is absorbed into the pulmonary lymphatics and transported to the CNS via the thoracic duct, bypassing systemic circulation entirely and producing immediate striatal dopamine replenishment within 3 to 5 minutes without peripheral dopaminergic side effects; apomorphine is reserved for patients who are unable to use the inhalation device due to cognitive or motor limitations.

10. A 74-year-old man with Parkinson's disease and atrial fibrillation is anticoagulated with warfarin with a stable INR of 2.4 over the past 6 months. His neurologist adds entacapone 200 mg with each of his four daily carbidopa/levodopa doses for wearing-off. Three weeks later his INR at a routine anticoagulation clinic visit is 3.8. He has had no dietary changes, missed no warfarin doses, and has started no other new medications. The anticoagulation nurse asks whether entacapone could be responsible. Which of the following best explains the pharmacokinetic basis for entacapone's effect on warfarin anticoagulation and the appropriate management response?

• A) Entacapone inhibits CYP2C9, the principal hepatic enzyme responsible for S-warfarin hydroxylation and clearance; by reducing S-warfarin metabolism, entacapone raises plasma S-warfarin concentrations and prolongs its anticoagulant effect; the management is reducing the warfarin dose by approximately 30% and rechecking the INR in one week; entacapone's CYP2C9 inhibition is dose-dependent and fully reversible upon discontinuation.
• B) Entacapone displaces warfarin from plasma albumin binding sites because both drugs compete for the same high-affinity albumin binding site; the free warfarin fraction increases from approximately 1% to approximately 3%, tripling the pharmacologically active concentration; the management is reducing warfarin by 50% and switching to a direct oral anticoagulant that does not share the albumin binding site with entacapone.
• C) Entacapone inhibits hepatic COMT, which is responsible for O-methylation of the hydroxyl groups on warfarin's coumarin ring; by blocking warfarin's primary hepatic inactivation pathway, entacapone substantially extends warfarin's plasma half-life; management is holding warfarin for 48 hours and restarting at 75% of the prior dose with weekly INR monitoring until restabilized.
• D) Entacapone inhibits CYP2C9 in vitro and has been shown in pharmacokinetic studies to increase the area under the curve of S-warfarin, the more potent warfarin enantiomer; this interaction is documented in the entacapone prescribing information, which recommends monitoring INR when entacapone is added to or removed from a warfarin regimen; the management is acknowledging this as a probable entacapone-warfarin interaction, reducing the warfarin dose to bring the INR back to therapeutic range, and performing more frequent INR monitoring while entacapone therapy continues.
• E) Entacapone reduces hepatic blood flow by inhibiting peripheral COMT in mesenteric vascular endothelium, reducing the delivery of warfarin to hepatic CYP2C9 for first-pass clearance; the reduced hepatic extraction of warfarin on repeat-dose administration raises steady-state warfarin concentrations; management is switching entacapone to tolcapone, which does not affect mesenteric blood flow and does not interact with warfarin pharmacokinetics.

11. A 58-year-old man with Parkinson's disease diagnosed at age 49 has been on carbidopa/levodopa for 7 years and now has severe peak-dose dyskinesia that is functionally disabling — involuntary choreiform movements for 4 to 5 hours daily — despite dose reduction and extended-release amantadine 274 mg nightly. He has minimal cognitive impairment (MoCA 27/30), good motor benefit from levodopa when not dyskinetic, and 5 to 6 hours of good quality on-time daily when not troubled by dyskinesia. His neurologist discusses advanced therapy options. Which of the following best describes the comparative pharmacological and practical basis for choosing between deep brain stimulation (DBS) of the subthalamic nucleus and LCIG infusion for this patient, and identifies the clinical factors favoring one approach?

• A) Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is generally favored over LCIG for this patient for several interconnected reasons: DBS modulates basal ganglia circuitry through high-frequency electrical stimulation of the STN, which reduces the overactive subthalamic drive on the globus pallidus interna and restores more physiological thalamo-cortical motor output — this mechanism is independent of levodopa pharmacokinetics and can substantially reduce dyskinesia while allowing the levodopa dose to be reduced by 50 to 60% postoperatively (the dose reduction itself further reduces dyskinesia); DBS also provides adjustable, reversible neuromodulation without the GI complications of a PEG-J tube; in younger patients with good cognitive function (as in this patient — MoCA 27/30), favorable anatomy, and a predominantly dyskinesia-dominant motor complication profile, DBS has a strong evidence base and is the preferred advanced therapy; LCIG reduces dyskinesia through continuous levodopa delivery that eliminates plasma peaks but requires PEG-J placement, carries carbidopa-associated peripheral neuropathy risk with long-term use, and does not reduce total levodopa exposure to the same degree as the DBS-enabled dose reduction.
• B) LCIG is preferred over DBS for this patient because its continuous levodopa delivery eliminates the plasma levodopa peaks responsible for peak-dose dyskinesia without the neurosurgical risks of DBS; the DBS-enabled levodopa dose reduction is not a reliable benefit because most patients require dose re-escalation within 2 years as the DBS effect wanes from electrode impedance changes; LCIG's efficacy for dyskinesia reduction is superior to DBS in all published head-to-head trials, establishing it as the standard of care for young patients with dyskinesia-dominant complications.
• C) Neither DBS nor LCIG addresses the underlying molecular mechanism of levodopa-induced dyskinesia — deltaFosB accumulation and NMDA receptor plasticity in striatal medium spiny neurons — and both are therefore palliative at best; the correct management for this patient is gene therapy delivering AADC to surviving nigrostriatal neurons via AAV2 vector, which restores regulated dopamine synthesis and eliminates pulsatile stimulation by generating tonic dopamine independent of levodopa dosing; this approach has been approved by the FDA for young-onset PD with refractory dyskinesia.
• D) The choice between DBS and LCIG for dyskinesia management is determined solely by the patient's levodopa dose at the time of evaluation; patients on more than 800 mg levodopa daily require DBS because their high dopamine burden exceeds what continuous LCIG delivery can buffer; patients on less than 800 mg daily should receive LCIG because the lower dopamine load is compatible with the continuous delivery pharmacokinetics that LCIG provides; this patient's levodopa dose must be calculated before the therapeutic decision can be made.
• E) DBS is contraindicated in patients under 60 years of age with young-onset PD because the rapidly progressing neurodegeneration in this population causes electrode migration within 18 months; LCIG is the preferred advanced therapy for all young-onset PD patients for this reason, and DBS should be reserved for patients over 70 years with stable disease in whom electrode stability is predictable over the shorter remaining treatment duration.